Question explored with the scientific record
Does the shingles vaccine prevent one from contracting shingles
The shingles vaccine substantially reduces the risk of developing shingles, but it does not eliminate it entirely.
The most direct evidence comes from a 2024 meta-analysis of 7 randomized trials in immunocompromised adults. The recombinant zoster vaccine (Shingrix) reduced herpes zoster incidence by about 81% compared to placebo [2]. In the key ZOE-50 and ZOE-70 trials, funded by the manufacturer GSK, efficacy against confirmed shingles was 97.2% for adults aged 50 and older, and 89.8% for those 70 and older [3, 8]. A pooled analysis of those trials in adults with pre-existing immune-mediated diseases found 90.5% efficacy [7]. So the vaccine works well, but it is not perfect.
Breakthrough cases do occur. A 2025 case report documented a 74-year-old man who developed herpes zoster ophthalmicus (shingles in the eye) despite having received both Shingrix shots a few years earlier [4]. Real-world data from a 2021-2025 Italian study of high-risk patients found that 26 out of 787 vaccinated people, about 3.3%, developed shingles over the follow-up period [6]. Among those followed for more than two years, the incidence dropped to about 0.05 cases per 100 person-days [6].
The live-attenuated zoster vaccine (Zostavax) is less effective. It reduced shingles by about 51% in a large Medicare study of chronic kidney disease patients [1], and by roughly 48% overall [1]. That vaccine is largely being replaced by Shingrix, which has a stronger safety profile in the VAERS data (2.9% serious reports versus 27.6% for Zostavax) [5], though it causes more temporary injection-site reactions [2, 6].
My call: the recombinant shingles vaccine provides strong, though not absolute, protection against shingles. The evidence shows it reduces risk by roughly 80-97% depending on age and health status, but breakthrough cases happen, especially in the highest-risk individuals. Confidence: high for efficacy, moderate for long-term durability of protection.
Sources used 8
-
Zoster vaccination is associated with a reduction of zoster in elderly patients with chronic kidney disease
Using a large 5% sample of US Medicare (2007–2009), this population-based cohort found that zoster vaccination significantly reduced incident herpes zoster in older adults with chronic kidney disease (VE ≈49% in CKD and ≈46% in CKD with diabetes), with effectiveness comparable t…
DOI: 10.1093/ndt/gfv432 -
Systematic review and meta-analysis of recombinant herpes zoster vaccine in immunocompromised populations
In a meta-analysis of 7 RCTs in immunocompromised adults, recombinant zoster vaccine reduced herpes zoster incidence by 81% versus placebo and increased humoral and cellular immune responses, with higher local/general reactogenicity but no difference in unsolicited or fatal adve…
DOI: 10.1371/journal.pone.0313889 -
Impact of varicella vaccination on the epidemiology of herpes zoster and postherpetic neuralgia: a narrative review
Varicella vaccination reduced pediatric herpes zoster and did not accelerate adult HZ incidence, though a Korean pediatric HZ surge after a 2018 vaccine strain highlights reactogenicity; recombinant zoster vaccine offers 85% efficacy for older adults.
DOI: 10.12701/jyms.2026.43.22 -
Herpes zoster ophthalmicus despite shingrix immunization
A 74-year-old man with comorbidities developed herpes zoster ophthalmicus despite prior Shingrix vaccination; combination therapy led to near-complete ocular recovery within about three weeks.
DOI: 10.15406/aovs.2025.15.00484 -
Safety profile of herpes zoster vaccines in the United States: a descriptive and disproportionality analysis of adverse events reported to the vaccine adverse event reporting system (VAERS), 2017–2024
In 69,822 US VAERS reports (2017-2024), herpes zoster vaccine adverse-event reporting was dominated by transient reactogenicity and injection-site reactions, with serious reports uncommon overall (6.6%) and for Shingrix (2.9%) but more frequent for Zostavax (27.6%), largely driv…
DOI: 10.3389/fmed.2026.1920596 -
Safety profile and medium- to long-term protection of the Recombinant Zoster Vaccine (RZV) in a cohort of high-risk patients: real-world data from a General Hospital in Southern Italy, 2021–2025
A prospective real-world study in a Southern Italian hospital evaluated the safety, disease-flare potential, and medium-to-long-term protection against herpes zoster after Recombinant Zoster Vaccine (RZV) in a medically diverse, vulnerable adult population, finding acceptable sa…
DOI: 10.1080/14760584.2025.2589216 -
Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials
In a pooled post hoc analysis of the ZOE-50/70 trials, the adjuvanted recombinant zoster vaccine was 90.5% efficacious against herpes zoster in adults with pre-existing potential immune-mediated diseases, with SAE and fatal SAE rates similar to placebo.
DOI: 10.1093/rheumatology/keaa424 -
Vaccines in Dermatology—Present and Future: A Review
This 2025 review surveys current and emerging vaccines in dermatology, assessing platforms, safety, efficacy, and immunogenicity across acne, HPV-related diseases, varicella/zoster, melanoma, atopic dermatitis, warts, fungal and bacterial skin infections, neglected tropical dise…
DOI: 10.3390/vaccines13020125